Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC

This trial tests combining an immunotherapy drug (tislelizumab) with chemotherapy and chest radiation for extensive-stage small cell lung cancer — a fast-growing lung cancer that has spread at the time of diagnosis. The goal is to improve survival beyond standard chemotherapy alone. **You may be eligible if...** - You are aged 18–80 with confirmed extensive-stage small cell lung cancer - You have not yet received treatment for this stage of the disease - You have at least one measurable tumor on imaging - You are in good physical condition and expected to survive at least 3 months **You may NOT be eligible if...** - You have previously received chemotherapy or radiation for extensive-stage SCLC - Your vital organ functions (liver, kidneys, heart) are significantly compromised - You have serious autoimmune disease or recent major infection Talk to your doctor to see if this trial is right for you.